AR043120A1 - Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos - Google Patents

Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos

Info

Publication number
AR043120A1
AR043120A1 ARP040100385A ARP040100385A AR043120A1 AR 043120 A1 AR043120 A1 AR 043120A1 AR P040100385 A ARP040100385 A AR P040100385A AR P040100385 A ARP040100385 A AR P040100385A AR 043120 A1 AR043120 A1 AR 043120A1
Authority
AR
Argentina
Prior art keywords
compounds described
formula
compounds
stimulators
glycerides
Prior art date
Application number
ARP040100385A
Other languages
English (en)
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of AR043120A1 publication Critical patent/AR043120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de uno o más compuestos para la preparación de un medicamento para estimular la eritropoyesis, donde dichos compuestos se seleccionan del grupo que comprende a los compuestos descriptos en las fórmula (1), (2) y (3) y combinaciones de los mismos; en donde R1 es un grupo alquilo C7-11 saturado o insaturado, de cadena recta o ramificada, A y B son H o R1-C, y A no es necesariamente idéntica a B; y X es un grupo hidroxilo, un anión oxi con un contraión metálico mono- o dicatiónico, o un grupo alcoxi con una fracción alquilo C1-4 de cadena recta o ramificada. El medicamento se emplea en un método para estimular la eritropoyesis en un paciente que necesite el tratamiento y se administra en una cantidad de manera tal que se encuentra presente en una concentración de médula ósea de modo que forme micetas o agregados anfipáticos similares. Composición farmacéutica para estimular la eritropoyesis en un paciente que necesite el tratamiento, en donde dicha composición comprende una cantidad farmacológicamente afectiva de uno o más compuestos descriptos por la fórmula (1) uno o más compuestos descriptos por la fórmula (2), compuestos descriptos por la fórmula (3) , o una combinación de los mismos. Dicha composición puede contener eritropoyetina. Tal como caprilato de calcio, caprato de calcio entre otros.
ARP040100385A 2003-02-07 2004-02-06 Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos AR043120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07

Publications (1)

Publication Number Publication Date
AR043120A1 true AR043120A1 (es) 2005-07-20

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100385A AR043120A1 (es) 2003-02-07 2004-02-06 Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos

Country Status (28)

Country Link
US (1) US9682054B2 (es)
EP (1) EP1592416B1 (es)
JP (1) JP5390070B2 (es)
KR (1) KR101120775B1 (es)
CN (1) CN100427081C (es)
AP (1) AP2005003367A0 (es)
AR (1) AR043120A1 (es)
AT (1) ATE419846T1 (es)
AU (1) AU2004210193B2 (es)
BR (1) BRPI0407276A (es)
CA (1) CA2515160C (es)
CY (1) CY1108963T1 (es)
DE (2) DE602004018902D1 (es)
DK (1) DK1592416T3 (es)
EA (1) EA009939B1 (es)
ES (1) ES2255467T3 (es)
IL (1) IL170057A (es)
JO (1) JO2705B1 (es)
MA (1) MA27664A1 (es)
MX (1) MXPA05008382A (es)
MY (1) MY140913A (es)
NO (1) NO334085B1 (es)
NZ (1) NZ541593A (es)
PT (1) PT1592416E (es)
SI (1) SI1592416T1 (es)
TN (1) TNSN05189A1 (es)
WO (1) WO2004069237A1 (es)
ZA (1) ZA200506246B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12772003A3 (sk) 2001-04-18 2004-07-07 Prometic Biosciences Inc. Stredne dlhé mastné kyseliny, glyceridy a analógy ako faktory prežitia a aktivácie neutrofilov
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
ZA200701781B (en) * 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
ZA200702532B (en) * 2004-10-01 2008-11-26 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
NZ584981A (en) 2007-11-02 2012-05-25 Prometic Biosciences Inc Medium-chain length fatty acids and glycerides as nephroprotection agents
CA2708679C (en) * 2007-12-19 2016-11-15 Prometic Biosciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
SI2343982T1 (sl) 2008-09-17 2017-08-31 Chiasma Inc. Farmacevtski sestavki in metode povezane z dostavo
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
AU2010263182B2 (en) 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
RS64214B1 (sr) 2014-12-03 2023-06-30 Celgene Corp Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6054441A (en) * 1987-10-28 2000-04-25 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
IT1275802B1 (it) 1994-11-03 1997-10-17 Hoffmann La Roche Composizione di interferone
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
AU9221698A (en) * 1997-09-04 1999-03-22 Biozone Laboratories, Inc. Oral liposomal delivery system
ES2384094T3 (es) * 1997-11-14 2012-06-29 Pacira Pharmaceuticals, Inc. Producción de liposomas multivesiculares
WO1999025312A1 (en) * 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
DE69833333T2 (de) * 1997-11-20 2006-10-19 Jhon, Gil Ja Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
ES2224299T3 (es) * 1998-02-23 2005-03-01 Cilag Ag International Dispersion liposomal de eritroyetina.
ATE246506T1 (de) 1998-03-11 2003-08-15 Grelan Pharmaceutical Co Darmlösliche sprudelnde zusammensetzungen
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2001022937A1 (en) * 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1289530B1 (en) 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
SK12772003A3 (sk) * 2001-04-18 2004-07-07 Prometic Biosciences Inc. Stredne dlhé mastné kyseliny, glyceridy a analógy ako faktory prežitia a aktivácie neutrofilov
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
ES2284029T5 (es) 2003-07-25 2012-02-17 Prometic Biosciences Inc. Preparación de sales metálicas de ácidos grasos de cadena media.
ZA200701781B (en) * 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
EP1592416B1 (en) 2009-01-07
MY140913A (en) 2010-01-29
WO2004069237A1 (en) 2004-08-19
DE04708802T1 (de) 2006-06-22
ATE419846T1 (de) 2009-01-15
CN1753665A (zh) 2006-03-29
ES2255467T1 (es) 2006-07-01
US9682054B2 (en) 2017-06-20
US20060128800A1 (en) 2006-06-15
DE602004018902D1 (de) 2009-02-26
EA200501267A1 (ru) 2006-02-24
NO20053994D0 (no) 2005-08-26
NZ541593A (en) 2009-05-31
DK1592416T3 (da) 2009-04-20
NO20053994L (no) 2005-10-06
KR20050118671A (ko) 2005-12-19
KR101120775B1 (ko) 2012-04-18
EA009939B1 (ru) 2008-04-28
CA2515160C (en) 2013-01-08
JO2705B1 (ar) 2014-03-15
EP1592416A1 (en) 2005-11-09
CY1108963T1 (el) 2014-07-02
ZA200506246B (en) 2006-12-27
AU2004210193B2 (en) 2007-07-12
BRPI0407276A (pt) 2006-01-31
CN100427081C (zh) 2008-10-22
MXPA05008382A (es) 2005-11-04
NO334085B1 (no) 2013-12-09
MA27664A1 (fr) 2005-12-01
TNSN05189A1 (en) 2007-06-11
CA2515160A1 (en) 2004-08-19
ES2255467T3 (es) 2009-05-01
JP5390070B2 (ja) 2014-01-15
JP2006516987A (ja) 2006-07-13
AU2004210193A1 (en) 2004-08-19
AP2005003367A0 (en) 2005-09-30
PT1592416E (pt) 2009-04-03
SI1592416T1 (sl) 2009-06-30
IL170057A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
AR043120A1 (es) Acidos grasos de longitud de cadena mediana, gliceridos y analogos como estimuladores de la produccion de progenitores de eritrocitos
RU2144356C1 (ru) Композиция для инъекций на основе таксоидов
ES2248272T5 (es) Formulación de fulvestrant
FI68173B (fi) Foerfarande foer framstaellning av lokalanestesiskt verksamma kombinationspreparat
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
UY29321A1 (es) Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de ácidos grasos
ECSP034563A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos
CN1430503A (zh) 制剂
GEP20002069B (en) Taxoid Based Pharmaceutical Compositions and Method for its Production
BR0209320A (pt) ésteres de uridina farmaceuticamente ativos
MX2008012844A (es) Composiciones farmaceuticas y usos de ellas.
AR030007A1 (es) Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento
JP6052929B2 (ja) 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
JP2003171301A (ja) 歯周炎治療における補助剤としてのカルメグゲル
CO5380014A1 (es) Formulacion farmaceuticas para la administracion oral o topica de compuestos hidrofobicos que no frma emulsion
US10603278B2 (en) Microspheres containing anthelmintic macrocyclic lactones
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
RU2302861C3 (ru) Лекарственное средство для лечения вирусных кожных и опухолевых заболеваний
DE07108593T1 (de) Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse
EA200401565A1 (ru) Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
AR029302A1 (es) Compuesto de fenilo 1,4-sustituido, el uso del mismo para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene y proceso para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal